<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vasculitis in children: Management overview</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vasculitis in children: Management overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Vasculitis in children: Management overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Cabral, MBBS, FRCPC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kimberly Morishita, MD, MHSc, FRCPC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Sundel, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marisa Klein-Gitelman, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Vasculitis is defined as the presence of inflammation in a blood vessel that may occur as a primary process or secondary to an underlying disease. Clinical symptoms vary widely. The various vasculitic syndromes are defined by both the type of pathologic inflammation and the type and location of the predominantly involved vessels, which, in turn, determines which specific organs are affected [<a href="#rid1">1,2</a>].</p><p>The first priorities in management of a child with vasculitis are prompt recognition and timely treatment since many of the vasculitides can be severe and life threatening if not appropriately managed. Specific treatments are determined by the type of vasculitis, the severity of the inflammation, and the particular organ systems affected.</p><p>A general overview of the management of vasculitis in children is reviewed here. The classification and the approach to evaluating childhood vasculitis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6401.html" rel="external">"Vasculitis in children: Incidence and classification"</a> and  <a class="medical medical_review" href="/z/d/html/6430.html" rel="external">"Vasculitis in children: Evaluation overview"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL PRINCIPLES OF MANAGEMENT</span><span class="headingEndMark"> — </span>The following principles are important to consider when managing a child with vasculitis:</p><p class="bulletIndent1"><span class="glyph">●</span>Differentiating vasculitis from other diseases that can either mimic vasculitis or cause secondary vasculitis</p><p class="bulletIndent1"><span class="glyph">●</span>Defining disease activity and severity</p><p class="bulletIndent1"><span class="glyph">●</span>Weighing the benefits and risks of therapy</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Differentiating vasculitis from other diseases</span><span class="headingEndMark"> — </span>In treating a child with vasculitis, it is critical to distinguish primary vasculitis from other diseases that can mimic vasculitis, as well as from conditions causing secondary vasculitis, such as infections, drugs, malignancies, or connective tissue diseases (eg, systemic lupus erythematosus and juvenile dermatomyositis). Making an accurate diagnosis is necessary to ensure that the appropriate therapy is given and contraindicated medicines avoided. In children with secondary vasculitis, therapy is directed at treating the underlying disease (eg, infection or other rheumatic disorders). Thus, administration of immunosuppressive therapy may be appropriate in patients with primary vasculitis but may have adverse (even catastrophic) consequences in a patient with secondary vasculitis due to a systemic infection. The disorders that may mimic vasculitis or cause secondary vasculitis are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6430.html" rel="external">"Vasculitis in children: Evaluation overview", section on 'Differentiating primary vasculitis from other disorders'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Defining disease activity</span><span class="headingEndMark"> — </span>Assessment of disease activity plays an important role in the treatment of the systemic vasculitides, both in interpreting the results of therapeutic studies and in directing the care for individual patients [<a href="#rid3">3</a>]. Patients may fall into one of three categories of active disease or may be in remission.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Active disease</strong> – A patient has active disease when there is objective evidence of ongoing inflammation. However, determining this is not always straightforward, because there is a lack of reliable disease-activity markers for many types of systemic vasculitis. In addition, distinguishing active disease from chronic sequelae of the disease (irreversible damage), medication toxicity, and concomitant or secondary processes, such as infection, may be difficult. Because of the lack of reliable markers, assessment of disease activity often relies upon the clinical judgment of the treating clinician(s) based upon clinical findings (eg, signs, symptoms, disease tempo, and laboratory markers of inflammation, such as erythrocyte sedimentation rate or C-reactive protein). The ability to detect and quantify disease activity is important as it impacts upon therapeutic choices. (See <a class="local">'Patient monitoring'</a> below.)</p><p></p><p class="bulletIndent1">The three categories of active disease are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>New-onset disease</strong> – Disease at the time of diagnosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Relapsing disease</strong> – When disease activity recurs following remission.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory disease</strong> – Worsening disease or persisting disease activity with limited improvement after a period of appropriate therapy (eg, within a few days for Kawasaki disease after two treatments with intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">immune globulin</a> [IVIG] or within 6 to 12 weeks of standard "remission induction" therapy for chronic diseases such as granulomatosis with polyangiitis [GPA]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Remission</strong> – A patient is in remission when there is persistently no evidence of active disease. There is no universally accepted duration of persistent inactivity required to define remission, and definitions vary considerably within the literature. In some studies, remission may be as long as three months for chronic vasculitides (eg, Takayasu arteritis) and as short as 24 to 48 hours for acute conditions (eg, Kawasaki disease). Remission may be further qualified as remission on or off medications.</p><p></p><p>In the management of childhood vasculitis, treatment is determined by the phase of disease activity as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction therapy</strong> – Therapy is directed at stopping the inflammatory process in a newly diagnosed patient and putting the patient into remission.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance therapy</strong> – Once the patient is in remission, therapy may be continued to maintain remission. In some cases, especially in diseases that are generally acute and self-limited (eg, Kawasaki disease), maintenance therapy may not be necessary, and the patient may be in remission off medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapse therapy</strong> – Therapy that is required to treat a reactivation of the inflammatory process.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory therapy</strong> – Increased therapy requirement for patients not responding to standard therapy, which may include alternative or additional immunosuppression or biologic response modifiers. (See appropriate topic reviews for each specific vasculitis disorder.)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Weighing the benefits and risks of therapy</span><span class="headingEndMark"> — </span>When deciding upon therapy for any given vasculitis, the benefits of a specific therapy and its potential adverse effects must be weighed against the consequences of allowing the vascular inflammation to follow its natural course. Treatment of the rarer types of chronic vasculitis is best supervised by clinicians (eg, pediatric rheumatologists) with knowledge of the diseases, medications used to treat them, and the implications of the disease and its treatment in a developing child. The importance of judiciously balancing the short- and long-term risks of treatment against the short- and long-term risks of untreated disease cannot be overstated.</p><p>Some vasculitides, such as immunoglobulin A (IgA) vasculitis (Henoch-Schönlein purpura), are acute, usually self-limited, and uncomplicated. In these cases, it is usually unnecessary to even consider the use of potentially toxic therapies.</p><p>Other vasculitides, such as GPA, follow a chronic relapsing course with ongoing serious morbidity and mortality risk due to kidney disease and/or pulmonary involvement. In such patients, long-term immunosuppressive therapy is usually warranted in an attempt to minimize disease relapses and/or progression.</p><p>Children require special consideration regarding both short-term and long-term calculations of treatment risks and benefits. Both the disease and its treatments affect physical, social, educational, and emotional development and can have long-term consequences. Children are presumed to have a long life expectancy, so the significance of potentially lifesaving treatment is magnified. Children's developing organ systems are at risk of insidiously accruing a high toxic burden from therapies. With time, the potential long-term toxicities (eg, infertility, malignancy, osteoporosis, atherosclerosis) have a greater chance to manifest.</p><p class="headingAnchor" id="H6"><span class="h2">Determining what treatment is warranted</span><span class="headingEndMark"> — </span>The treatment of primary vasculitic syndromes varies based upon the answers to the following key questions [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Is the disease active? Differentiate active disease from chronic sequelae of disease, medication toxicity, and other processes, particularly infection. For refractory disease, in particular, alternative or additional diagnoses/diseases should be considered. (See  <a class="medical medical_review" href="/z/d/html/6430.html" rel="external">"Vasculitis in children: Evaluation overview", section on 'Differentiating primary vasculitis from other disorders'</a> and <a class="local">'Defining disease activity'</a> above and <a class="local">'Patient monitoring'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>How severe is the active disease? Fulminant life-threatening disease or critical organ-threatening disease requires more aggressive management. (See <a class="local">'Patient monitoring'</a> below and  <a class="medical medical_review" href="/z/d/html/6430.html" rel="external">"Vasculitis in children: Evaluation overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>What organ sites are affected? Certain sites of organ involvement may not require or may not respond to systemic immunosuppressive therapy. As an example, subglottic stenosis in GPA may be more appropriately treated with local therapy (eg, local glucocorticoid injections and/or mechanical dilation) than with systemic medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Is this an acute, self-limited disease such as Kawasaki disease where there is a short window of opportunity for preventing damage and long-term immunosuppressive treatment is not usually required, or is it IgA vasculitis, when no toxic therapy may be necessary?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>What accommodations should be made for unique characteristics of individual patients?</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Is there a history of medication toxicity or intolerability?</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Is there a contraindication to certain medications?</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Does the presence of previous organ damage restrict therapeutic options?</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Does the patient's age or sex constrain options?</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Do patient/caregiver preferences, tolerance of risk, or ability to comply with medication regimens strongly weigh for or against certain approaches?</p><p></p><p class="headingAnchor" id="H7"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The treatment of vasculitis depends upon the nature and severity of the disorder. Treatment options may include antihistamines, nonsteroidal antiinflammatory drugs (NSAIDs), glucocorticoids, or immunosuppressive agents (eg, <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a>, biologic response modifiers). While there are recommended, standardized protocols for initiating treatment of moderate-to-severe chronic vasculitis in adult patients, such protocols are seldom validated in pediatric patients. Accordingly, such protocols should be used as a suggested approach rather than firm guidelines for children and adolescents with vasculitis. In an effort to improve upon pediatric-specific treatment guidance, consensus-based recommendations for the management of rare chronic systemic pediatric vasculitides were published in 2019 [<a href="#rid5">5</a>]. Subsequently, consensus treatment plans (CTPs) for the treatment of severe pediatric antineutrophil cytoplasmic autoantibody (ANCA) associated vasculitis were published [<a href="#rid6">6</a>]. Such consensus-based recommendations and treatment protocols, ideally for use within a registry, represent an important step towards developing a pediatric-specific evidence base to guide management of these patients.</p><p>An overview of the general principles of the management of vasculitis is presented here. Specific recommendations, including dosing regimens and detailed discussions of the individual disorders, are presented separately. (See appropriate topic reviews for each specific type of vasculitis.)</p><p>As discussed above (see <a class="local">'General principles of management'</a> above), the treatment of primary vasculitic syndromes will vary based upon the following factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Specific type of vasculitis [<a href="#rid7">7,8</a>] and, in particular, distinguishing primary from secondary vasculitis. In the latter case, therapy often is directed at treating the underlying disease (eg, infection or other rheumatic disorders). (See  <a class="medical medical_review" href="/z/d/html/6401.html" rel="external">"Vasculitis in children: Incidence and classification"</a> and  <a class="medical medical_review" href="/z/d/html/6430.html" rel="external">"Vasculitis in children: Evaluation overview", section on 'Differentiating primary vasculitis from other disorders'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type, extent, and severity of organ involvement: Localized (eg, cutaneous) vasculitis versus systemic involvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute self-limited (eg, IgA vasculitis and Kawasaki disease) versus chronic-relapsing systemic disorders (eg, granulomatosis with polyangiitis [GPA], Takayasu arteritis, polyarteritis nodosa, and microscopic polyangiitis).</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Cutaneous vasculitis</span><span class="headingEndMark"> — </span>Management consists mainly of supportive measures when vascular inflammation is limited to the skin (such as mild cases of IgA vasculitis or isolated cutaneous leukocytoclastic vasculitis). (See  <a class="medical medical_review" href="/z/d/html/6407.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Management"</a> and  <a class="medical medical_review" href="/z/d/html/8241.html" rel="external">"Overview of cutaneous small vessel vasculitis", section on 'Treatment'</a>.)</p><p>In patients with mild hypersensitivity vasculitis due to a drug reaction, discontinuation of the offending drug may be adequate. Other supportive measures include antihistamines, which may relieve the itching associated with urticaria, and NSAIDs, which may provide analgesia. (See  <a class="medical medical_review" href="/z/d/html/6404.html" rel="external">"Hypersensitivity vasculitis in children", section on 'Treatment'</a>.)</p><p>In cases of cutaneous vasculitis where the course is more prolonged, severe, or chronic, such as cutaneous polyarteritis nodosa, a trial of <a class="drug drug_pediatric" data-topicid="13179" href="/z/d/drug information/13179.html" rel="external">colchicine</a>, <a class="drug drug_pediatric" data-topicid="13205" href="/z/d/drug information/13205.html" rel="external">dapsone</a>, oral glucocorticoids, or <a class="drug drug_pediatric" data-topicid="12923" href="/z/d/drug information/12923.html" rel="external">azathioprine</a> may be added to supportive measures [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H622893362"><span class="h2">Central nervous system vasculitis</span><span class="headingEndMark"> — </span>Central nervous system (CNS) vasculitis refers to a broad spectrum of diseases characterized by inflammation of the blood vessels of the brain, spinal cord, and/or meninges. Childhood primary angiitis of the CNS (cPACNS) is a vasculitis that is confined to the CNS. Treatment protocols for the different types of cPACNS have been developed and are reviewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/16367.html" rel="external">"Childhood primary angiitis of the central nervous system: Angiography-positive subtype"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Systemic vasculitis</span><span class="headingEndMark"> — </span>The treatment of primary systemic vasculitis in children varies depending upon whether the disorder is acute and self-limited or chronic with potentially frequent relapses.</p><p class="headingAnchor" id="H10"><span class="h3">Acute and self-limited disorders</span><span class="headingEndMark"> — </span>The two most common primary vasculitides, IgA vasculitis and Kawasaki disease, typically present acutely and are usually characterized by a self-limited course. Management is based upon an understanding of the well-characterized course of these diseases, the risk of long-term sequelae, and the effectiveness of available therapy as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>IgA vasculitis </strong>– Since IgA vasculitis is usually self-limited, without major long-term complications, patient management is primarily supportive, with therapy focused on symptomatic relief of arthritis and abdominal pain while systematically monitoring for kidney involvement. Glucocorticoids appear to improve joint and gastrointestinal symptoms in children with IgA vasculitis who do not respond to supportive therapy [<a href="#rid10">10</a>], but there is no strong evidence to suggest that they prevent the development of kidney disease [<a href="#rid11">11,12</a>]. However, treatment options for kidney disease, managed in consultation with a pediatric nephrologist, include glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and/or other immune-suppressing agents [<a href="#rid11">11,12</a>]. (See  <a class="medical medical_review" href="/z/d/html/6407.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kawasaki disease</strong> – The acute clinical manifestations of Kawasaki disease are generally self-limited. However, cardiac complications (particularly coronary artery aneurysms) may develop and lead to significant morbidity and mortality. As a result, patients with Kawasaki disease are treated during the acute phase of the disorder to reduce the risk of coronary artery aneurysms. In randomized clinical trials, the administration of intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG), in conjunction with <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">aspirin</a>, dramatically reduced the risk of aneurysms in children with Kawasaki disease. For children who fail to respond to the initial standard therapy of IVIG and aspirin, other immunosuppressive agents may be used. The initial treatment of Kawasaki disease, refractory therapy, and cardiovascular complications of Kawasaki disease are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">"Kawasaki disease: Initial treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/6408.html" rel="external">"Refractory Kawasaki disease"</a> and  <a class="medical medical_review" href="/z/d/html/5772.html" rel="external">"Cardiovascular sequelae of Kawasaki disease: Clinical features and evaluation"</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h3">Chronic disorders</span><span class="headingEndMark"> — </span>Unlike IgA vasculitis and Kawasaki disease, other primary systemic vasculitides (such as Takayasu arteritis, GPA, polyarteritis nodosa, microscopic polyangiitis, and eosinophilic GPA [Churg-Strauss syndrome]) are characterized by chronic, often relapsing, disease courses. Children with primary chronic systemic vasculitis should be cared for by experienced clinicians (eg, pediatric rheumatologists) who are familiar with the different primary vasculitides and their treatment. Management should always be based upon the best available evidence published in the literature while taking into consideration factors specific to individual patients such as disease activity, severity, and tolerance of medications. Glucocorticoids, with <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a> for more severe disease, have been the standard of care for many types of primary chronic vasculitides. Other immunosuppressive drugs, such as <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">methotrexate</a> and <a class="drug drug_pediatric" data-topicid="12923" href="/z/d/drug information/12923.html" rel="external">azathioprine</a>, as well as biologic agents (eg, tumor necrosis factor [TNF] inhibitors, <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a>, and <a class="drug drug_pediatric" data-topicid="88097" href="/z/d/drug information/88097.html" rel="external">tocilizumab</a>), have shown benefit in small studies of various pediatric systemic vasculitides and are increasingly being used [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H4155302017"><span class="h4">Remission induction and remission maintenance therapy</span><span class="headingEndMark"> — </span>The results of adult studies have important implications for children because they demonstrate that milder, more localized disease can be treated effectively with less aggressive treatment protocols. Glucocorticoid therapy alone may be sufficient initially for mild and limited disease, but an additional immunosuppressive agent is generally indicated for moderate-to-severe systemic disease that is life or organ threatening (eg, kidney, lung, or brain involvement). Patients with severe systemic vasculitis are usually treated in a staged treatment approach [<a href="#rid14">14</a>] with high-dose glucocorticoids plus a potent immunosuppressive agent to induce remission. Subsequently, remission is maintained with lower-dose glucocorticoids and continuing immunosuppressive therapy of lower potency/toxicity. Treatment protocols emphasize early administration of steroid-sparing agents in order to minimize exposure to glucocorticoids.</p><p>The standard initial glucocorticoid therapy for most of the systemic vasculitides is <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a>/<a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> 1 to 2 mg/kg per day (maximum dose 60 mg per day), given for two to four weeks before systematically and gradually reducing the dose as symptoms improve. The goal is to reach low doses (0.2 mg/kg/day or 10 mg/day, whichever is lower) by six months [<a href="#rid5">5,6,15</a>]. In patients with severe or life-threatening disease, glucocorticoid treatment may begin with high pulsed doses of intravenous <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">methylprednisolone</a> (IVMP; ie, 30 mg/kg per day for one to three days, maximum dose of 1 gram/day) followed by oral therapy. Adult guidelines for treating GPA published in 2021 [<a href="#rid16">16</a>] advise cautionary use of pulsed IVMP because of its lack of proven efficacy and known side effects [<a href="#rid17">17,18</a>]; they also recommend early and more aggressive oral glucocorticoid wean based upon adult study data [<a href="#rid15">15</a>]. None of these adult glucocorticoid studies have been replicated in children.</p><p><a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">Cyclophosphamide</a> is the traditional first-choice immunosuppressive agent, in addition to glucocorticoids, to induce remission in moderate-to-severe chronic vasculitis (eg, polyarteritis nodosum and antineutrophil cytoplasmic antibody [ANCA] associated vasculitides [AAVs] such as GPA, microscopic polyangiitis, and eosinophilic GPA). The use of cyclophosphamide in children is based upon improved remission rates and survival in trials of adults with these diseases [<a href="#rid14">14,19-23</a>]. Takayasu arteritis, on the other hand, often responds to <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">methotrexate</a> or biologic response modifiers [<a href="#rid24">24-26</a>]. Less potent and less toxic than cyclophosphamide, methotrexate is increasingly used as initial therapy for less severe early disease [<a href="#rid21">21,27-30</a>], and both methotrexate and <a class="drug drug_pediatric" data-topicid="12923" href="/z/d/drug information/12923.html" rel="external">azathioprine</a> are frequently used for maintenance therapy [<a href="#rid14">14,31-33</a>].</p><p>Adult studies suggest that <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a>, a monoclonal antibody that depletes B cells, is as safe and effective as <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a> for inducing [<a href="#rid34">34-36</a>] and maintaining [<a href="#rid37">37-40</a>] remission, leading to greater use of this drug for induction therapy in children with AAV in the US [<a href="#rid41">41</a>]. The risk for prolonged hypogammaglobulinemia post-rituximab therapy recognized in adults [<a href="#rid42">42</a>] may be higher in children. At least 4 percent of children require prophylactic intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG) to prevent infection, but the true extent and duration of this problem are still being characterized [<a href="#rid43">43-46</a>]. The long-term consequences of this may impact treatment choices for children versus adults. In the absence of pediatric-specific data about the longer-term risks of rituximab, guidelines recommend its use in patients with refractory disease who have failed cyclophosphamide, have relapsing disease, or when specific concerns exist regarding cyclophosphamide toxicity [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H2108534143"><span class="h4">Therapy for refractory or relapsing disease</span><span class="headingEndMark"> — </span>In severe systemic vasculitides, many agents may successfully induce disease remission, but well over half of patients relapse. Such relapses can cause cumulative, irreversible end-organ damage resulting in significant morbidity over time. The cumulative toxicity from repeated courses of <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a> can also lead to significant morbidity; hence, alternative agents are being tested for remission maintenance.</p><p>In adult trials, <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a> dosed every six months appears to effectively maintain disease remission in AAV with minimal side effects other than a dose-dependent risk of hypogammaglobulinemia [<a href="#rid37">37-40</a>]. Similarly, maintenance therapy with anti-tumor necrosis factor (TNF) agents and anti-interleukin (IL) 6 monoclonal antibodies in Takayasu arteritis may offer an effective alternative to more conventional immunosuppressive agents [<a href="#rid26">26,38,47-50</a>]. No comparable trials have been conducted in pediatric systemic vasculitis, although such biologic response modifiers are increasingly used to treat pediatric patients with disease that is refractory to conventional treatment (<a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a> and glucocorticoids) or those with relapsing disease [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy"</a> and  <a class="medical medical_review" href="/z/d/html/3040.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Management of relapsing disease"</a> and  <a class="medical medical_review" href="/z/d/html/8219.html" rel="external">"Treatment of Takayasu arteritis"</a>.)</p><p class="headingAnchor" id="H870181450"><span class="h4">Adjunctive therapy for severe disease</span><span class="headingEndMark"> — </span>There is no evidence to support the routine use of plasmapheresis in the treatment of AAV. Earlier studies in adults had suggested that plasma exchange may reduce the risk of dialysis dependence and end-stage kidney disease [<a href="#rid52">52,53</a>]. However, there was no apparent survival benefit. Results from the Plasma Exchange and Glucocorticoid Dosing in the Treatment of ANCA-Associated Vasculitis (PEXIVAS) trial evaluating the role of plasmapheresis in AAV showed that plasma exchange does not reduce the risk of end-stage kidney disease or death in patients with AAV [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Supportive care</span><span class="headingEndMark"> — </span>Some manifestations of vasculitis (eg, neuropathy) may take months to recede because of the slow recovery of end-organ damage, even when the underlying vasculitis is no longer active. In other cases, end-organ damage is irreversible, resulting in permanent clinical abnormalities. For example, patients in remission may continue to have seizures or learning disabilities due to residual brain damage or hypertension due to kidney damage, both of which were incurred during the period of active vasculitis. These and other chronic complications need to be addressed and treated accordingly with both pharmacologic and nonpharmacologic therapies.</p><p>The impact of these chronic disorders and their treatments upon the physical, educational, and psychosocial development of a growing child or adolescent should not be underestimated. It represents an additional arena of morbidity compared with adults with vasculitis. Important areas of potential concern include reduced physical fitness, excessive or inadequate weight gain, delayed puberty, reduced growth, impaired academic performance and career potential, limited participation in extracurricular activities, and depression.</p><p>In addition to the pharmacologic management of immunosuppression by the clinician, children with severe systemic vasculitis are best cared for by a multidisciplinary team. Other medical subspecialists and health care professionals including nurses, physical and occupational therapists, social workers, and psychologists are team members who provide clinical care, counseling, referral to community services, and communication with the primary care clinician and school.</p><p class="headingAnchor" id="H13"><span class="h1">PATIENT MONITORING</span><span class="headingEndMark"> — </span>The goal of initial therapy is to induce remission of the disease. Once this has been accomplished, a balance must be achieved between maintaining remission and minimizing treatment-related toxicities. In order to do this, patients must be monitored on a regular basis for signs of disease activity as well as medication side effects. It is important to remember that most forms of primary systemic vasculitis (except for IgA vasculitis and Kawasaki disease) tend to be chronic and relapsing. Distinguishing among active disease, chronic sequelae of disease, and treatment-related side effects can be challenging. Therefore, thorough and regular follow-up evaluations are necessary, even when the patient appears entirely well.</p><p>Patient monitoring relies upon some, but not all, of the procedures used in diagnosis including clinical findings, laboratory tests, imaging studies, and tissue biopsy. (See  <a class="medical medical_review" href="/z/d/html/6430.html" rel="external">"Vasculitis in children: Evaluation overview"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Depending upon the organ predilection of a patient's vasculitis, certain symptoms and signs may provide reliable evidence of active disease, and, therefore, they are included in routine monitoring. Worsening kidney function or deteriorating pulmonary function tests may herald a relapse of AAV, seizures or behavioral changes may indicate reactivation of childhood primary angiitis of the central nervous system (cPACNS), and bruits and new sites of claudication may result from progressive Takayasu arteritis. Other features are not always attributable to vascular inflammation, and other signs and symptoms, such as headaches, fatigue, and worsening hypertension, are less clearly attributable to the active inflammation of vasculitis. In addition, vessel damage may progress in some types of vasculitis despite a complete lack of symptoms and entirely normal acute-phase reactants [<a href="#rid54">54</a>]. In these settings, monitoring disease activity with the aid of laboratory tests, repeat imaging studies, or formal cognitive or pulmonary function testing is often essential.</p><p class="headingAnchor" id="H15"><span class="h2">Laboratory tests</span><span class="headingEndMark"> — </span>The following laboratory tests are used to monitor disease activity:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute-phase reactants</strong> – Erythrocyte sedimentation rate (ESR), serum C-reactive protein (CRP), and platelet count, among others, are nonspecific markers of inflammation. Elevations of these tests may be indicative of increased disease activity. Acute changes in conjunction with other clinical findings or persistent abnormalities not accounted for by intercurrent illnesses or other factors must be investigated carefully.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urinalysis</strong> – Monitoring with urinalyses on a regular basis can detect changes in the urinary sediment that may reflect active disease in vasculitides that target the kidneys. Changes in the urinary sediment may also be due to persistent kidney damage from earlier active disease or medication toxicity, such as hematuria from cyclophosphamide-associated hemorrhagic cystitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antineutrophil cytoplasmic antibody (ANCA) titers</strong> – The utility of ANCA titers to predict active disease or risk of flares in ANCA-positive vasculitides remains controversial and is an area of ongoing study. Total ANCA levels do not seem to correlate with disease activity, but specific antigenic targets of antineutrophil cytoplasm antibodies (such as proteinase 3 [PR3] and myeloperoxidase [MPO] ANCA) may more closely reflect active vasculitis. Based upon available data, ANCA titers should not be used in isolation when making treatment decisions. This question is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/3040.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Management of relapsing disease", section on 'Monitoring by the clinician'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Von Willebrand factor (VWF)</strong> <strong>antigen</strong> – VWF antigen, and perhaps other markers of endothelial cell disruption, may be useful for following damage to blood vessels, as occurs in vasculitis. In certain cases, such proteins may provide a more specific marker of disease activity than other acute-phase reactants [<a href="#rid55">55,56</a>].</p><p></p><p>Laboratory tests are also ordered for the purpose of monitoring medication toxicity, such as reduced cell counts in patients receiving immunosuppressive therapy, or elevated transaminases in those taking <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">methotrexate</a>.</p><p class="headingAnchor" id="H16"><span class="h2">Imaging studies</span><span class="headingEndMark"> — </span>Imaging studies of vessels or of major organs, such as the brain or lungs, may be necessary to distinguish whether clinical symptoms reflect active disease or prior damage. These studies, which include ultrasonography, echocardiography, computed tomography (CT), and magnetic resonance imaging (MRI), may be used at regular intervals, even in the absence of symptoms, in order to monitor disease progression and response to treatment. As previously discussed, many laboratory markers are nonspecific and/or may not reliably correlate with disease activity. Thus, it is often necessary to use imaging as part of follow-up evaluations. Other types of studies evaluating end-organ function, such as pulmonary function tests, may also be helpful.</p><p>Although conventional angiography may be necessary in the initial diagnostic evaluation of some systemic vasculitides, less invasive modalities, such as ultrasonography or magnetic resonance angiography, are preferred for continued routine monitoring, reserving more invasive testing for those situations in which more accurate imaging is required for critical therapeutic decisions.</p><p class="headingAnchor" id="H17"><span class="h2">Tissue biopsy</span><span class="headingEndMark"> — </span>If the patient had an initial biopsy and the findings were diagnostic, often little more is to be learned by repeating the procedure as part of ongoing monitoring. On the other hand, if the patient's original diagnosis is in question, a new illness is suspected, or ongoing disease activity must be distinguished from manifestations of irreversible damage, repeat biopsies may be useful. This is particularly likely to be the case with kidney involvement, although involvement of other organs also must be assessed in this way on occasion.</p><p class="headingAnchor" id="H18"><span class="h2">Disease-activity scoring</span><span class="headingEndMark"> — </span>Formalized scoring tools, such as the Birmingham Vasculitis Activity Score (BVAS), that are used to determine disease activity at the time of diagnosis are increasingly used to monitor disease activity and response to therapy. Fluctuations in scores are used to adjust medication dosing or choice of therapy for adults with vasculitis, both in the investigational and clinical practice setting. These tools are sometimes used for children with or without some pediatric-specific adaptations, although most of these tools have not been validated for use in pediatrics. As an example, the Pediatric Vasculitis Activity Score (PVAS), an adaptation of the BVAS, was internally validated [<a href="#rid57">57</a>]. Although external validation of this tool on an independent dataset would be valuable, it has already been used as a standard measure of disease in one pediatric vasculitis clinical trial.</p><p class="headingAnchor" id="H19"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Outcomes are dependent upon numerous factors including the specific diagnosis, disease severity, involvement of major organs, response to treatment, and damage caused by treatment.</p><p>The majority of children with primary vasculitis have a good outcome because the two most common disorders, Kawasaki disease and IgA vasculitis, are usually self-limited, and only a small minority of children have long-term sequelae from either damage or ongoing disease activity. (See  <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">"Kawasaki disease: Initial treatment and prognosis", section on 'Prognosis'</a> and  <a class="medical medical_review" href="/z/d/html/6407.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Management", section on 'Prognosis'</a>.)</p><p>For the other primary systemic vasculitides, immunosuppressive therapy has improved survival and remission rates. As an example, prior to the introduction of the regimen of high-dose glucocorticoids and <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a>, granulomatosis with polyangiitis (GPA) was fatal in almost all reported pediatric [<a href="#rid58">58</a>] and adult cases. The reported median survival time was five months in untreated adults [<a href="#rid59">59</a>]. The combination of glucocorticoids and cyclophosphamide or other remittive agents has greatly improved patient outcomes. Similar therapeutic strategies have proven beneficial in the treatment of other systemic vasculitides. (See  <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy"</a> and  <a class="medical medical_review" href="/z/d/html/8244.html" rel="external">"Treatment and prognosis of polyarteritis nodosa"</a> and  <a class="medical medical_review" href="/z/d/html/8219.html" rel="external">"Treatment of Takayasu arteritis"</a>.)</p><p>A 2008 systematic review of mortality risk in patients with systemic vasculitis that included both adult and pediatric patients reported the following five-year survival rates: GPA (approximately 75 percent), microscopic polyangiitis (45 to 75 percent), eosinophilic GPA (68 to 100 percent), IgA vasculitis (75 percent in adult onset, greater in childhood onset), medium vessel vasculitis including polyarteritis nodosa (75 to 80 percent), Kawasaki disease (greater than 99 percent at five years), and Takayasu arteritis (70 to 93 percent) [<a href="#rid60">60</a>].</p><p>One study of early outcomes in 105 children with antineutrophil cytoplasmic antibody (ANCA) associated vasculitides (AAV) reported remission rates of 42 percent and improvement rates of 92 percent at 12 months [<a href="#rid61">61</a>]. Unfortunately, more than half of the cohort had evidence of damage at 12 months despite high improvement rates and aggressive treatment. No patients in the cohort died during the 12-month follow-up period.</p><p>Despite improved remission and survival rates, relapse is still common, especially when therapy is weaned or stopped [<a href="#rid62">62-64</a>]. Flares of GPA occur in up to 83 percent of pediatric patients as treatment is weaned [<a href="#rid62">62,64</a>]. A high rate of relapse (approximately 75 percent) is also seen in patients with polyarteritis nodosa [<a href="#rid64">64</a>]. Lower relapse rates are seen in eosinophilic GPA and microscopic polyangiitis (50 and 33 percent, respectively). As a result, maintenance immunosuppression is commonly used in these disorders. (See  <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Maintenance therapy'</a>.)</p><p>Irreversible tissue damage is another crucial index of outcome. Measurement tools, such as the Vasculitis Damage Index (VDI), are widely used in adult chronic vasculitis to formally quantify damage due to either disease or treatment [<a href="#rid65">65</a>]. These tools, modified to incorporate measurements of damage unique to development and growth in children, are essential for the better understanding of childhood outcomes. A pediatric adaptation of the VDI (pVDI) has been developed, although it is not yet validated.</p><p class="headingAnchor" id="H2926446288"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110743.html" rel="external">"Society guideline links: Vasculitis"</a>.)</p><p class="headingAnchor" id="H248878017"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/86015.html" rel="external">"Patient education: Vasculitis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Vasculitis is defined as the presence of inflammation in a blood vessel, which may occur as a primary process or secondary to an underlying disease. Prompt recognition and treatment of these disorders are important as they can be severe and even life-threatening conditions without timely therapy. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Principles that are important in managing a child with vasculitis include differentiating primary vasculitis from other conditions that may mimic vasculitis or cause secondary vasculitis, defining disease activity and severity, and weighing the benefits and risks of therapy. (See <a class="local">'General principles of management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management decisions, including which therapy to use in an individual patient, are based upon answers to key questions regarding the specific type of vasculitis; the course, activity, and severity of the disease; the type and extent of organ involvement; and unique patient characteristics/preferences. (See <a class="local">'Determining what treatment is warranted'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The treatment of vasculitis depends upon the nature and severity of the disorder (see <a class="local">'Treatment'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In children with secondary vasculitis, therapy is directed at treating the underlying disease (eg, infection, malignancy, or other rheumatic disorders).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In children with cutaneous vasculitis (ie, vascular inflammation limited to the skin), supportive measures are generally all that is required. This includes the use of antihistamines, which relieve urticarial itching, and nonsteroidal antiinflammatory drugs (NSAIDs), which provide analgesia. (See <a class="local">'Cutaneous vasculitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In children with acute, self-limited systemic vasculitides, particularly immunoglobulin A (IgA) vasculitis (Henoch-Schönlein purpura) and Kawasaki disease (the two most common types of primary vasculitis in children), treatment choice is based upon understanding the well-characterized course of the specific disease, the risk of long-term sequelae, and the effectiveness of available therapy. (See <a class="local">'Acute and self-limited disorders'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In children with chronic or frequently relapsing vasculitis, immunosuppressive therapy is used to induce and maintain remission. Glucocorticoids are the mainstay of therapy and may be sufficient as monotherapy in patients with mild or limited disease. However, in patients with severe or life-threatening disease, additional immunosuppressive agents or biologic response modifiers are generally needed. For refractory or frequently relapsing disease following standard induction therapy, <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a> is an option in children with antineutrophil cytoplasmic antibody (ANCA) associated vasculitis, and <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a> or <a class="drug drug_pediatric" data-topicid="88097" href="/z/d/drug information/88097.html" rel="external">tocilizumab</a> are options in children with Takayasu disease. (See <a class="local">'Chronic disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Once the patient is in remission, monitoring on a regular basis is required to detect signs of disease reactivation and/or drug toxicity. Follow-up measures include monitoring clinical manifestations of disease (eg, fever, claudication, skin lesions, or headache), laboratory testing (eg, acute-phase reactants and urinalysis), and imaging studies of vessels or of major organs to detect active disease versus residual damage. Tissue biopsy is usually not needed to monitor disease activity. (See <a class="local">'Patient monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The outcome of childhood vasculitis is dependent upon the specific diagnosis, disease severity, whether major organs are involved, response to treatment, and damage caused by treatment. (See <a class="local">'Outcomes'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Cabral DA, Ozen S, Morishita KA. Vasculitis and its classification. In: Textbook of Pediatric Rheumatology, 8th ed, Petty RE, Laxer RM, Lindsley CB, et al (Eds), Elsevier, 2021. p.451.</li><li><a class="nounderline abstract_t">Schnabel A, Hedrich CM. Childhood Vasculitis. Front Pediatr 2018; 6:421.</a></li><li><a class="nounderline abstract_t">Luqmani RA. State of the art in the treatment of systemic vasculitides. Front Immunol 2014; 5:471.</a></li><li><a class="nounderline abstract_t">Langford CA. Management of systemic vasculitis. Best Pract Res Clin Rheumatol 2001; 15:281.</a></li><li><a class="nounderline abstract_t">de Graeff N, Groot N, Brogan P, et al. European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides - the SHARE initiative. Rheumatology (Oxford) 2019; 58:656.</a></li><li><a class="nounderline abstract_t">Morishita KA, Wagner-Weiner L, Yen EY, et al. Consensus Treatment Plans for Severe Pediatric Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken) 2022; 74:1550.</a></li><li><a class="nounderline abstract_t">Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187.</a></li><li><a class="nounderline abstract_t">Watts RA, Suppiah R, Merkel PA, Luqmani R. Systemic vasculitis--is it time to reclassify? Rheumatology (Oxford) 2011; 50:643.</a></li><li><a class="nounderline abstract_t">Micheletti RG, Pagnoux C. Management of cutaneous vasculitis. Presse Med 2020; 49:104033.</a></li><li><a class="nounderline abstract_t">Saulsbury FT. Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore) 1999; 78:395.</a></li><li><a class="nounderline abstract_t">Gohari A, Matsell DG, Mammen C, Goldman RD. Henoch-Schönlein purpura in children: Use of corticosteroids for prevention and treatment of renal disease. Can Fam Physician 2020; 66:895.</a></li><li><a class="nounderline abstract_t">Ozen S, Marks SD, Brogan P, et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford) 2019; 58:1607.</a></li><li><a class="nounderline abstract_t">Morishita K, Brown K, Cabral D. Pediatric vasculitis: advances in treatment. Curr Opin Rheumatol 2015; 27:493.</a></li><li><a class="nounderline abstract_t">Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003; 114:463.</a></li><li><a class="nounderline abstract_t">Walsh M, Merkel PA, Peh CA, et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med 2020; 382:622.</a></li><li><a class="nounderline abstract_t">Mendel A, Ennis D, Go E, et al. CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update. J Rheumatol 2021; 48:555.</a></li><li><a class="nounderline abstract_t">Chanouzas D, McGregor JAG, Nightingale P, et al. Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study. BMC Nephrol 2019; 20:58.</a></li><li><a class="nounderline abstract_t">Huang L, Zhong Y, Ooi JD, et al. The effect of pulse methylprednisolone induction therapy in Chinese patients with dialysis-dependent MPO-ANCA associated vasculitis. Int Immunopharmacol 2019; 76:105883.</a></li><li><a class="nounderline abstract_t">Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68:310.</a></li><li><a class="nounderline abstract_t">Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016; 75:1583.</a></li><li><a class="nounderline abstract_t">Jayne D. How to induce remission in primary systemic vasculitis. Best Pract Res Clin Rheumatol 2005; 19:293.</a></li><li><a class="nounderline abstract_t">Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44:666.</a></li><li><a class="nounderline abstract_t">Bourgarit A, Le Toumelin P, Pagnoux C, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005; 84:323.</a></li><li><a class="nounderline abstract_t">Hoffman GS, Leavitt RY, Kerr GS, et al. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994; 37:578.</a></li><li><a class="nounderline abstract_t">Barra L, Yang G, Pagnoux C, Canadian Vasculitis Network (CanVasc). Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: A systematic review and meta-analysis. Autoimmun Rev 2018; 17:683.</a></li><li><a class="nounderline abstract_t">Alibaz-Oner F, Kaymaz-Tahra S, Bayındır Ö, et al. Biologic treatments in Takayasu's Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumab. Semin Arthritis Rheum 2021; 51:1224.</a></li><li><a class="nounderline abstract_t">De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:2461.</a></li><li><a class="nounderline abstract_t">Langford CA, Sneller MC, Hoffman GS. Methotrexate use in systemic vasculitis. Rheum Dis Clin North Am 1997; 23:841.</a></li><li><a class="nounderline abstract_t">Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000; 43:1836.</a></li><li><a class="nounderline abstract_t">Stone JH, Tun W, Hellman DB. Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 1999; 26:1134.</a></li><li><a class="nounderline abstract_t">Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42:2666.</a></li><li><a class="nounderline abstract_t">Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36.</a></li><li><a class="nounderline abstract_t">Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359:2790.</a></li><li><a class="nounderline abstract_t">Geetha D, Kallenberg C, Stone JH, et al. Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab. J Nephrol 2015; 28:17.</a></li><li><a class="nounderline abstract_t">Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211.</a></li><li><a class="nounderline abstract_t">Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221.</a></li><li><a class="nounderline abstract_t">Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371:1771.</a></li><li><a class="nounderline abstract_t">Singer O, McCune WJ. Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. Curr Opin Rheumatol 2017; 29:248.</a></li><li><a class="nounderline abstract_t">Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 2012; 64:3770.</a></li><li><a class="nounderline abstract_t">Thiel J, Troilo A, Salzer U, et al. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis. J Allergy Clin Immunol Pract 2017; 5:1556.</a></li><li><a class="nounderline abstract_t">James KE, Xiao R, Merkel PA, Weiss PF. Variation in the Treatment of Children Hospitalized With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the US. Arthritis Care Res (Hoboken) 2017; 69:1377.</a></li><li><a class="nounderline abstract_t">Roberts DM, Jones RB, Smith RM, et al. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. J Autoimmun 2015; 57:24.</a></li><li><a class="nounderline abstract_t">Khojah AM, Miller ML, Klein-Gitelman MS, et al. Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases. Pediatr Rheumatol Online J 2019; 17:61.</a></li><li><a class="nounderline abstract_t">Padoan R, Felicetti M, Gatto M, et al. Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study. Clin Exp Rheumatol 2020; 38 Suppl 124:188.</a></li><li><a class="nounderline abstract_t">Labrosse R, Barmettler S, Derfalvi B, et al. Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients. J Allergy Clin Immunol 2021; 148:523.</a></li><li><a class="nounderline abstract_t">Mitchell C, Crayne CB, Cron RQ. Patterns of B Cell Repletion Following Rituximab Therapy in a Pediatric Rheumatology Cohort. ACR Open Rheumatol 2019; 1:527.</a></li><li><a class="nounderline abstract_t">Stern S, Clemente G, Reiff A, et al. Treatment of Pediatric Takayasu arteritis with infliximab and cyclophosphamide: experience from an American-Brazilian cohort study. J Clin Rheumatol 2014; 20:183.</a></li><li><a class="nounderline abstract_t">Szugye HS, Zeft AS, Spalding SJ. Takayasu Arteritis in the pediatric population: a contemporary United States-based single center cohort. Pediatr Rheumatol Online J 2014; 12:21.</a></li><li><a class="nounderline abstract_t">Goel R, Kumar TS, Danda D, et al. Childhood-onset Takayasu arteritis -- experience from a tertiary care center in South India. J Rheumatol 2014; 41:1183.</a></li><li><a class="nounderline abstract_t">Cañas CA, Cañas F, Izquierdo JH, et al. Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis. J Clin Rheumatol 2014; 20:125.</a></li><li><a class="nounderline abstract_t">Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 2012; 51:634.</a></li><li><a class="nounderline abstract_t">Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18:2180.</a></li><li><a class="nounderline abstract_t">Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis--a clinical randomized controlled trial. Nephrol Dial Transplant 2011; 26:206.</a></li><li><a class="nounderline abstract_t">Tann OR, Tulloh RM, Hamilton MC. Takayasu's disease: a review. Cardiol Young 2008; 18:250.</a></li><li><a class="nounderline abstract_t">Fazzini F, Peri G, Doni A, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001; 44:2841.</a></li><li><a class="nounderline abstract_t">Jakob A, Schachinger E, Klau S, et al. Von Willebrand factor parameters as potential biomarkers for disease activity and coronary artery lesion in patients with Kawasaki disease. Eur J Pediatr 2020; 179:377.</a></li><li><a class="nounderline abstract_t">Dolezalova P, Price-Kuehne FE, Özen S, et al. Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann Rheum Dis 2013; 72:1628.</a></li><li><a class="nounderline abstract_t">Moorthy AV, Chesney RW, Segar WE, Groshong T. Wegener granulomatosis in childhood: prolonged survival following cytotoxic therapy. J Pediatr 1977; 91:616.</a></li><li><a class="nounderline abstract_t">WALTON EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958; 2:265.</a></li><li><a class="nounderline abstract_t">Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol 2008; 26:S94.</a></li><li><a class="nounderline abstract_t">Morishita KA, Moorthy LN, Lubieniecka JM, et al. Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol 2017; 69:1470.</a></li><li><a class="nounderline abstract_t">Rottem M, Fauci AS, Hallahan CW, et al. Wegener granulomatosis in children and adolescents: clinical presentation and outcome. J Pediatr 1993; 122:26.</a></li><li><a class="nounderline abstract_t">Akikusa JD, Schneider R, Harvey EA, et al. Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis Rheum 2007; 57:837.</a></li><li><a class="nounderline abstract_t">Iudici M, Puéchal X, Pagnoux C, et al. Brief Report: Childhood-Onset Systemic Necrotizing Vasculitides: Long-Term Data From the French Vasculitis Study Group Registry. Arthritis Rheumatol 2015; 67:1959.</a></li><li><a class="nounderline abstract_t">Exley AR, Carruthers DM, Luqmani RA, et al. Damage occurs early in systemic vasculitis and is an index of outcome. QJM 1997; 90:391.</a></li></ol></div><div id="topicVersionRevision">Topic 6403 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cabral DA, Ozen S, Morishita KA. Vasculitis and its classification. In: Textbook of Pediatric Rheumatology, 8th ed, Petty RE, Laxer RM, Lindsley CB, et al (Eds), Elsevier, 2021. p.451.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30687686" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Childhood Vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25352843" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : State of the art in the treatment of systemic vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11469822" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Management of systemic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30535249" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides - the SHARE initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33675161" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Consensus Treatment Plans for Severe Pediatric Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8129773" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Nomenclature of systemic vasculitides. Proposal of an international consensus conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647295" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Systemic vasculitis--is it time to reclassify?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32645416" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Management of cutaneous vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10575422" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33334956" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Henoch-Schönlein purpura in children: Use of corticosteroids for prevention and treatment of renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30879080" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26147755" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pediatric vasculitis: advances in treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12727579" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32053298" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32934123" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30777023" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31536905" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The effect of pulse methylprednisolone induction therapy in Chinese patients with dialysis-dependent MPO-ANCA associated vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18413444" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : EULAR recommendations for the management of primary small and medium vessel vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27338776" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15857797" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : How to induce remission in primary systemic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11263782" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16148732" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7908520" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29729444" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34706312" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Biologic treatments in Takayasu's Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16052573" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9361158" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Methotrexate use in systemic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10943874" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10332980" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10616016" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12840090" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19109574" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25185728" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647198" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647199" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Rituximab versus cyclophosphamide for ANCA-associated vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25372085" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28306595" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22730028" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28916432" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27813340" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Variation in the Treatment of Children Hospitalized With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25586449" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31462263" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32441645" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33862010" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31777835" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Patterns of B Cell Repletion Following Rituximab Therapy in a Pediatric Rheumatology Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24847743" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Treatment of Pediatric Takayasu arteritis with infliximab and cyclophosphamide: experience from an American-Brazilian cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24955077" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Takayasu Arteritis in the pediatric population: a contemporary United States-based single center cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24786922" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Childhood-onset Takayasu arteritis -- experience from a tertiary care center in South India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24662551" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21613248" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17582159" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20577017" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis--a clinical randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18325145" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Takayasu's disease: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11762945" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31760507" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Von Willebrand factor parameters as potential biomarkers for disease activity and coronary artery lesion in patients with Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23100606" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/908985" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Wegener granulomatosis in childhood: prolonged survival following cytotoxic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13560836" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19026150" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Mortality in systemic vasculitis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28371513" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8419611" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Wegener granulomatosis in children and adolescents: clinical presentation and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17530684" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical features and outcome of pediatric Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25808634" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Brief Report: Childhood-Onset Systemic Necrotizing Vasculitides: Long-Term Data From the French Vasculitis Study Group Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9205677" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Damage occurs early in systemic vasculitis and is an index of outcome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
